Related Experiment Video
Updated: Aug 14, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Contemporary management of atrial fibrillation
1Department of Medicine, Norwalk Hospital, Connecticut.
Insights
As atrial fibrillation incidence rises with age, hypertension is a key risk factor. Management now favors beta-blockers or calcium channel blockers for rate control and anticoagulation for stroke prevention in high-risk patients.
Area of Science:
- Cardiology
- Geriatric Medicine
- Pharmacology
Background:
- The incidence of atrial fibrillation (AF) increases significantly with age, posing a growing challenge for healthcare providers.
- Hypertension is identified as the most prevalent risk factor associated with atrial fibrillation in both men and women.
Purpose of the Study:
- To review current management strategies for atrial fibrillation based on recent clinical studies.
- To provide guidance on rate control, anticoagulation, and antiarrhythmic therapy for patients with atrial fibrillation.
Main Methods:
- Literature review of published studies on atrial fibrillation management.
- Analysis of risk factors and treatment outcomes.
Main Results:
- Beta-blockers and calcium channel blockers are preferred for rate control over digoxin.
- Low-dose anticoagulation demonstrates efficacy in primary and secondary prevention of thromboembolism.
- Aspirin therapy is recommended for patients not eligible for anticoagulation.
- Low-dose amiodarone is considered the most effective antiarrhythmic, though its use remains debated.
Conclusions:
- Atrial fibrillation management is evolving, with updated recommendations for rate control and thromboembolism prevention.
- Risk stratification is crucial for determining anticoagulation needs, with specific criteria for low-risk patients.
- Careful consideration of antiarrhythmic therapy is necessary, highlighting the role and controversy of amiodarone.
Abstract:
The incidence of atrial fibrillation approximately doubled for every 10-year increment in age in the Framingham Heart Study cohort; thus physicians will be faced with an increasing patient population with atrial fibrillation. Hypertension is observed to be the most common associated risk factor in both sexes. The management of patients with atrial fibrillation is evolving as a result of a number of published studies. Calcium channel blockers and beta-blockers are emerging as the preferred choices for rate control rather than digoxin. Low-dose anticoagulation therapy has shown beneficial effects not only in primary prevention, but also for secondary prevention of thromboembolism. Thus, patients who cannot be successfully cardioverted should be anticoagulated if there are no contraindications (Table 3) and if they do not fall into the low-risk group--defined as patients under the age of 65 without risk factors (hypertension, diabetes, previous stroke). Patients not eligible for anticoagulation should be on aspirin therapy. Patients with lone atrial fibrillation are not at higher risk for thromboembolism than the general population; therefore, they can be managed without anticoagulation or antiplatelet therapy. Antiarrhythmic treatment should be approached cautiously; amiodarone in low doses is the most effective and safe treatment, but this remains controversial.
Related Concept Videos
01:25Mitral Regurgitation III: Medical Management
01:26Mitral Stenosis III: Medical Management
01:25Aortic Regurgitation III: Medical Management
01:21Rheumatic Heart Disease III: Medical Management
01:25Dysrhythmias VI: Management of Dysrhythmias
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias